Medscape is available in 5 Language Editions – Choose your Edition here.


Pediatric IgA Nephropathy Treatment & Management

  • Author: Mohammad Ilyas, MD, FAAP; Chief Editor: Craig B Langman, MD  more...
Updated: Feb 27, 2014

Medical Care

Immunoglobulin A (IgA) nephropathy (IgAN) is a therapeutic challenge for physicians. The optimal approach to the treatment of IgA nephropathy is uncertain. The slow progression of renal disease (ie, glomerular filtration rate [GFR] loss of 1-3 mL/min/y) hampers the ability to perform adequate studies. The 2 primary approaches to therapy for primary IgA nephropathy are nonimmunosuppressive interventions and immunosuppressive therapy.

Nonimmunosuppressive interventions to slow progression that are not specific to IgA nephropathy, include blood pressure control and, in patients with proteinuria, angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). In addition, statin therapy may be beneficial in patients with chronic kidney disease and serum low-density lipoprotein (LDL) cholesterol concentrations above goal values. Fish oil (omega-3 fatty acid) may be effective in selected patients.

Immunosuppressive therapy to treat the underlying inflammatory disease includes glucocorticoids with or without other immunosuppressive agents (eg, cyclophosphamide, cyclosporine, mycophenolate).

Not all patients need immunosuppressives; the selection of patients for therapy is based, in part, on the perceived risk of progressive kidney disease: (1) patients with isolated hematuria, (2) patients with persistent proteinuria, and (3) patients with more severe or rapidly progressive disease.

Patients with isolated hematuria, no or minimal proteinuria (< 500 mg/d), and a normal GFR typically are not treated and do not undergo biopsy and, therefore, are identified as having IgA nephropathy. However, these patients should be periodically monitored at 6- to 12-month intervals since they have an appreciable risk of progressive disease as manifested by increases in proteinuria, blood pressure, and serum creatinine.

Patients with persistent proteinuria (>500 mg/d), a normal or only slightly reduced GFR that is not declining rapidly, and only mild-to-moderate histologic abnormalities on renal biopsy are managed with nonimmunosuppressive therapies to slow progression and, perhaps, with fish oil.

Patients with more severe or rapidly progressive disease (nephrotic-range proteinuria or proteinuria persisting despite ACE inhibitor/ARB therapy, rising serum creatinine, and/or renal biopsy with more severe histologic abnormalities, but with no significant chronic changes) may benefit from immunosuppressive therapy in addition to nonimmunosuppressive interventions to slow disease progression.

The Oxford histologic classification system may assist to select patients with the worst prognosis at the time of renal biopsy.

Nonimmunosuppressive therapies

The 3 nonimmunosuppressive therapies in IgA nephropathy are (1) ACE inhibitors and/or , which are used blood pressure and/or proteinuria control to slow the rate of progression of the renal disease; (2) statin therapy, which is for lipid lowering in selected patients (with elevated LDL cholesterol) to lower cardiovascular risk, although no evidence is available to show that such therapy slows the rate of progression of renal disease; and (3) fish oil (omega-3 fatty acids at prescription strength and quality), but its role is less clear.

Angiotensin inhibition

Angiotensin inhibition with an ACE inhibitor or ARB slows the rate of progression of most proteinuric chronic kidney diseases, an effect that is mediated at least in part by lowering both the systemic blood pressure and the intraglomerular pressure, thereby minimizing both proteinuria and secondary glomerular injury (ie, not due to the primary glomerular disease itself).

Clinical trials supporting the efficacy of angiotensin inhibition in patients with IgA nephropathy are limited, but it is presumed that the mechanisms of secondary progression (ie, progression not due to the activity of the underlying disease) are similar to those in other forms of proteinuric chronic kidney disease. ACE inhibitors and ARBs significantly reduce protein excretion to a comparable degree compared with placebo or the dihydropyridine calcium channel blocker, an effect that is seen in normotensive as well as hypertensive patients.

Angiotensin inhibitors also lower the blood pressure, and evidence suggests that a goal blood pressure below the 90th percentile is associated with improved renal outcomes.[13]

Combination of ACE inhibitor and ARB

The addition of an ARB to an ACE inhibitor in patients with IgA nephropathy produces a further antiproteinuric effect.[14] This finding is consistent with meta-analyses, which found a significant (18-25%) greater reduction in proteinuria with combined ACE inhibitors and ARBs compared with monotherapy.[15] As mentioned above, a more pronounced antiproteinuric effect to below 1 g/day is a marker for better outcomes.

Despite these observations, the clinical role of combined therapy in the treatment of IgA nephropathy is uncertain. The authors suggest the use of combination ACE inhibitor and ARB therapy if the proteinuria goal of less than 500 mg/day is not reached with monotherapy at the maximum recommended dose.

Lipid-lowering therapy

Chronic kidney disease is associated with a marked increase in cardiovascular risk and is considered a coronary artery disease risk equivalent. The goal LDL cholesterol is similar to that in other patients.

Fish oil

The possible role of fish oil (prescription-strength omega-3 fatty acids, not over-the-counter food supplements) in patients with IgA nephropathy, which might act by anti-inflammatory mechanisms, is not well defined.[16]

Immunosuppressive therapy

The optimal role of immunosuppressive therapy IgA nephropathy is uncertain.[17] A variety of regimens have been used, mostly consisting of anti-inflammatory doses of glucocorticoids alone or in combination with other immunosuppressive drugs. Immunosuppressive therapy should only be attempted in patients with clinical evidence (eg, hematuria plus an increased serum creatinine or proteinuria value >1 g/day after maximal antiproteinuric therapy) and histologic evidence (eg, proliferative or necrotizing glomerular changes) of active inflammation.

Indications for immunosuppressive therapy

Indications for the use of glucocorticoids alone or in combination with other immunosuppressive agents in patients with IgA nephropathy are not well defined, and one must take into account the potential toxicity of these drugs. Most nephrologists do not treat mild, stable, or very slowly progressive IgA nephropathy with glucocorticoids or other immunosuppressive therapies.[18]

Immunosuppressive therapy should be considered only in patients with clinical features (eg, hematuria with an elevated or increasing serum creatinine value and/or protein excretion >1 g/day despite maximum antiproteinuric therapy) and histologic features (eg, active inflammation with necrotizing glomerular lesions) suggesting an adverse renal prognosis.

Patients with an acute onset of nephrotic syndrome and diffuse foot process fusion on renal biopsy are treated as if they have minimal change disease.

Glucocorticoids plus angiotensin inhibitors

Simultaneous treatment with glucocorticoids plus an angiotensin inhibitor is preferred to glucocorticoids alone and may be superior to angiotensin inhibitors alone.[19]

Glucocorticoids plus cyclophosphamide

Patients with severe or progressive disease (eg, rising creatinine, nephrotic-range proteinuria, and/or marked proliferation without crescents) who do not have significant evidence of chronic damage on kidney biopsy may benefit from combined immunosuppressive therapy with prednisone and cyclophosphamide.[20]

The treatment of crescentic, rapidly progressive glomerulonephritis in patients with IgA nephropathy has not been evaluated in randomized trials. Observational data suggest possible benefit from regimens similar to those used in idiopathic crescentic glomerulonephritis: intravenous pulse methylprednisolone followed by oral prednisone, intravenous or oral cyclophosphamide, and/or plasmapheresis.[21]

Mycophenolate mofetil

Data concerning the efficacy of mycophenolate mofetil (MMF) in the primary treatment of progressive IgA nephropathy are limited. The trials had conflicting results, ranging from no benefit, particularly in patients with advanced fibrotic disease,[22] to a reduction in proteinuria and a decrease in the rate of decline in the GFR.[23]

A short course (< 6 mo) of MMF may be considered in patients with hematuria, persistent proteinuria (>1.5 g/day), and a serum creatinine value of less than 1.5 mg/dL (133 µmol/L) despite maximum therapy with an angiotensin inhibitor in patients without marked glomerular or tubulointerstitial fibrosis on renal biopsy. Current evidence does not support the use of MMF in patients with advanced disease (serum creatinine >2.5 mg/dL).[24]


Cyclosporine has been investigated in small series of patients with IgA nephropathy. Although proteinuria may be reduced, the use of cyclosporine has been limited by the associated nephrotoxicity, leading to a rise in the serum creatinine concentration that is greater than that seen in untreated patients.[25] In addition, relapse occurs soon after the drug is discontinued.

Other possible interventions

Other interventions that have been evaluated in an uncontrolled fashion include tonsillectomy, a low-antigen diet, intravenous immunoglobulin (IVIG), and wormwood. Other drugs, such as vitamin D analogs, phenytoin, antiplatelet agent, and danazol, have also been evaluated but data are limited.


Tonsillitis has been associated with hematuria and proteinuria in IgA nephropathy. It has been proposed that the tonsils are a source of abnormal IgA that forms immune complexes and deposits in the glomeruli.[26] The role of tonsillectomy in IgA nephropathy remains unclear, but in several studies, tonsillectomy in combination with some immunosuppressive therapy improved renal outcomes in patients with relatively mild renal injury.[27] However, other studies reported no benefit following tonsillectomy.[28]

Low-antigen diet

A low-antigen diet consists of avoiding gluten, dairy products, eggs, and most meats. The rationale for this regimen is that dietary macromolecules may be responsible for activating the mucosal IgA system. When given to 21 consecutive patients with IgA nephropathy, protein excretion was markedly reduced or fell into the normal range in 11 of 12 patients whose baseline rate was more than 1 g/day. In addition, repeat renal biopsy showed significant reductions in mesangial IgA and complement deposition and mesangial cellularity.[29]

The benefits in the above study have not been confirmed, and a report describes using a gluten-free diet alone for several years that did not demonstrate improvement in either proteinuria or renal function despite a reduction in the level of circulating IgA-containing immune complexes.

Intravenous immunoglobulin

High-dose IVIG has been tried in severe IgA nephropathy characterized by heavy proteinuria and a relatively rapid decline in GFR.[30] Eleven patients (9 with IgA nephropathy and 2 with the related disorder Henoch-Schönlein purpura) were treated with IVIG at a dose of 1 g/kg for 2 days per month for 3 months, followed by an intramuscular preparation given every 2 weeks for another 6 months. IVIG therapy was associated with a reduction in protein excretion (5.2 to 2.3 g/day), prevention of a continued reduction in GFR (loss of 3.8 mL/min per month prior to therapy vs stable GFR after therapy), and decreased inflammatory activity and IgA deposition on repeat renal biopsy. The benefit of IVIG needs to be confirmed in a larger number of patients.


The herbal supplement wormwood (Artemisia absinthium) may inhibit inflammatory cytokines such as tumor necrosis factor-alpha and nuclear factor-kappa B. One study examined the effect of wormwood (1.8 g/day for 6 mo) on protein excretion in 10 patients with biopsy-proven IgA nephropathy, a creatinine clearance greater than 90 mL/min; and protein excretion greater than 500 mg/day despite angiotensin inhibition.[31] At 6 months, the mean urine protein-to-creatinine ratio decreased from 2.3 to 0.3. The reduction in proteinuria persisted for 6 months after stopping the herbal supplement. The creatinine clearance remained unchanged. The long-term effects of wormwood on the course of IgA nephropathy have not been evaluated.

Monitoring disease activity

There are no immunologic-specific markers to identify continued immunologic activity. As a result, clinical parameters are typically used, whether or not the patient is receiving immunosuppressive therapy. The major parameters that are serially monitored are the urine sediment, serum creatinine concentration or estimated GFR, and protein excretion.


Persistent hematuria is generally a marker of persistent immunologic activity, but not necessarily of progressive disease. Hematuria alone does not require any form of therapy, but monitoring over time is essential since some patients develop proteinuria and progressive disease.


Protein excretion above 1 g/day is a marker of more severe disease and is a major risk factor for disease progression unless the degree of proteinuria is reduced. Because of the prognostic importance of the degree of proteinuria, an initial 24-hour urine collection for both protein and creatinine is recommended. Increasing proteinuria may be due to ongoing active disease and/or secondary glomerular injury due to nonimmunologic progression. It is often not possible to distinguish between these 2 possibilities, except for a rapid increase in protein excretion, which is only seen with active disease.

Serum creatinine

Serum creatinine concentration, unless it is rapidly rising, permits an estimation of the GFR. Most patients with chronic IgA nephropathy have stable or slowly progressive disease. The rate of loss of GFR is often as low as 1-3 mL/min per year, a change that may not raise the serum creatinine level to above normal values for a number of years. Because of a compensatory rise in single-nephron GFR among less injured glomeruli, a stable normal serum creatinine level or estimated total kidney GFR does not necessarily indicate stable disease.


Pregnancy is generally well tolerated in patients with IgA nephropathy and a normal or near-normal GFR. As with most other chronic kidney diseases, the risk of worsening renal disease with pregnancy is increased in women with an initial GFR below 70 mL/min, uncontrolled hypertension, or severe arteriolar and tubulointerstitial disease on renal biopsy.[32]

Angiotensin inhibitors and some immunosuppressive drugs, particularly cyclophosphamide and MMF, should be discontinued at the earliest indication of pregnancy or prior to attempted conception because of risks to the fetus.

End-stage renal disease

Patients who progress to end-stage renal disease can be treated with dialysis or transplantation.


Surgical Care

Generally, surgical care is not necessary except for dialysis access or renal transplantation.

Renal transplantation

Transplantation is the treatment of choice for individuals with end-stage renal disease (ESRD) due to IgA nephropathy. Renal allografts in IgA nephropathy recipients exhibited a similar 10-year survival rate compared with allografts in recipients with either non–IgA glomerular or nonglomerular disease. Several retrospective analyses have found no increased risk of recurrence based on living versus deceased donor status.[33]

Histologic recurrence, with or without evidence of clinical disease, is observed in most cases. Recurrent of IgA deposition may result in a wide spectrum of manifestations, ranging from an incidentally noted histologic finding to mesangioproliferative glomerulonephritis associated with hematuria, proteinuria, and progressive renal dysfunction.[34]

It is possible that in some renal transplant recipients with primary IgA nephropathy, the donor source may have an effect on the timing and likelihood of recurrence in the allograft. Therefore, the expected advantage in allograft survival with a living-related compared with deceased donor source may be negated. Overall, however, there does not seem to be any basis for avoiding a living-related donor source, given the reported equivalence of graft survival independent of IgA nephropathy recurrence, the expected deceased donor waiting list time, and a reported decrease in patient mortality and increase in graft survival with earlier transplantation in relation to time on dialysis.[35]



Because IgA nephropathy has the potential to progress to end-stage renal disease, consultation with a pediatric nephrologist is necessary.



An American Heart Association step I diet is recommended for all children older than 2 years. Patients may require consultation with a dietitian to determine a renal diet if renal insufficiency develops.



Typically, no activity restriction is necessary.

Contributor Information and Disclosures

Mohammad Ilyas, MD, FAAP Assistant Professor of Pediatrics, University of Florida College of Medicine; Consulting Staff, Department of Pediatrics, Section of Nephrology, Wolfson Children Hospital and Shands Hospital Jacksonville

Mohammad Ilyas, MD, FAAP is a member of the following medical societies: American Academy of Pediatrics, American Society of Nephrology

Disclosure: Nothing to disclose.


Richard Neiberger, MD, PhD Director of Pediatric Renal Stone Disease Clinic, Associate Professor, Department of Pediatrics, Division of Nephrology, University of Florida College of Medicine and Shands Hospital

Richard Neiberger, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Federation for Medical Research, American Medical Association, American Society of Nephrology, American Society of Pediatric Nephrology, Christian Medical and Dental Associations, Florida Medical Association, International Society for Peritoneal Dialysis, International Society of Nephrology, National Kidney Foundation, New York Academy of Sciences, Shock Society, Sigma Xi, Southern Medical Association, Southern Society for Pediatric Research, Southwest Pediatric Nephrology Study Group

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Adrian Spitzer, MD Clinical Professor Emeritus, Department of Pediatrics, Albert Einstein College of Medicine

Adrian Spitzer, MD is a member of the following medical societies: American Academy of Pediatrics, American Federation for Medical Research, American Pediatric Society, American Society of Nephrology, American Society of Pediatric Nephrology, International Society of Nephrology, Society for Pediatric Research

Disclosure: Nothing to disclose.

Chief Editor

Craig B Langman, MD The Isaac A Abt, MD, Professor of Kidney Diseases, Northwestern University, The Feinberg School of Medicine; Division Head of Kidney Diseases, The Ann and Robert H Lurie Children's Hospital of Chicago

Craig B Langman, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Nephrology, International Society of Nephrology

Disclosure: Received income in an amount equal to or greater than $250 from: Alexion Pharmaceuticals; Raptor Pharmaceuticals; Eli Lilly and Company; Dicerna<br/>Received grant/research funds from NIH for none; Received grant/research funds from Raptor Pharmaceuticals, Inc for none; Received grant/research funds from Alexion Pharmaceuticals, Inc. for none; Received consulting fee from DiCerna Pharmaceutical Inc. for none.

Additional Contributors

Deogracias Pena, MD Medical Director of Dialysis, Medical Director of Pediatric Nephrology and Transplantation, Cook Children's Medical Center; Clinical Associate Professor, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Medical Director of Pediatric Nephrology, Florida Hospital for Children

Deogracias Pena, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society of Pediatric Nephrology

Disclosure: Nothing to disclose.

  1. D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004 May. 24(3):179-96. [Medline].

  2. Li LS; Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int. 2004 Sep. 66(3):920-3. [Medline].

  3. Novak J, Julian BA, Mestecky J, Renfrow MB. Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol. 2012 May. 34(3):365-82. [Medline].

  4. Segarra A. [Progress in understanding the pathogenesis of IgA nephropathy: new perspectives for the near future?]. Nefrologia. 2010. 30(5):501-7. [Medline].

  5. Narita I, Gejyo F. Pathogenetic significance of aberrant glycosylation of IgA1 in IgA nephropathy. Clin Exp Nephrol. 2008 Oct. 12(5):332-8. [Medline].

  6. Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011 Oct. 22(10):1795-803. [Medline].

  7. Yu HH, Chu KH, Yang YH, et al. Genetics and immunopathogenesis of IgA nephropathy. Clin Rev Allergy Immunol. 2011 Oct. 41(2):198-213. [Medline].

  8. Novak J, Moldoveanu Z, Julian BA, et al. Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system. Adv Otorhinolaryngol. 2011. 72:60-3. [Medline].

  9. [Guideline] Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009 Sep. 76(5):534-45. [Medline].

  10. Lai FM, Szeto CC, Choi PC, et al. Characterization of early IgA nephropathy. Am J Kidney Dis. 2000 Oct. 36(4):703-8. [Medline].

  11. Glassock RJ. Analyzing antibody activity in IgA nephropathy. J Clin Invest. 2009 Jun. 119(6):1450-2. [Medline]. [Full Text].

  12. Hasbargen JA, Copley JB. Utility of skin biopsy in the diagnosis of IgA nephropathy. Am J Kidney Dis. 1985 Aug. 6(2):100-2. [Medline].

  13. Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011 Apr. 22(4):752-61. [Medline]. [Full Text].

  14. Reich HN, Troyanov S, Scholey JW, Cattran DC. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007 Dec. 18(12):3177-83. [Medline].

  15. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008 Jan 1. 148(1):30-48. [Medline].

  16. Donadio JV Jr, Larson TS, Bergstralh EJ, Grande JP. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol. 2001 Apr. 12(4):791-9. [Medline]. [Full Text].

  17. Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int. 2006 Jun. 69(11):1939-44. [Medline].

  18. Floege J, Eitner F. Present and future therapy options in IgA-nephropathy. J Nephrol. 2005 Jul-Aug. 18(4):354-61. [Medline].

  19. Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009 Dec. 24(12):3694-701. [Medline].

  20. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol. 2002 Jan. 13(1):142-8. [Medline].

  21. Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant. 2003 Jul. 18(7):1321-9. [Medline].

  22. Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int. 2004 May. 65(5):1842-9. [Medline].

  23. Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int. 2010 Mar. 77(6):543-9. [Medline].

  24. Frisch G, Lin J, Rosenstock J, Markowitz G, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant. 2005 Oct. 20(10):2139-45. [Medline].

  25. Cattran DC. Current status of cyclosporin A in the treatment of membranous, IgA and membranoproliferative glomerulonephritis. Clin Nephrol. 1991. 35 Suppl 1:S43-7. [Medline].

  26. Béné MC, Faure GC, Hurault de Ligny B, de March AK. Clinical involvement of the tonsillar immune system in IgA nephropathy. Acta Otolaryngol Suppl. 2004 Dec. 10-4. [Medline].

  27. Xie Y, Chen X, Nishi S, Narita I, Gejyo F. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int. 2004 Apr. 65(4):1135-44. [Medline].

  28. Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol. 1999 Mar. 51(3):147-52. [Medline].

  29. Coppo R, Roccatello D, Amore A, et al. Effects of a gluten-free diet in primary IgA nephropathy. Clin Nephrol. 1990 Feb. 33(2):72-86. [Medline].

  30. Rostoker G, Desvaux-Belghiti D, Pilatte Y, et al. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schönlein purpura. Ann Intern Med. 1994 Mar 15. 120(6):476-84. [Medline].

  31. Krebs S, Omer B, Omer TN, Fliser D. Wormwood (Artemisia absinthium) for poorly responsive early-stage IgA nephropathy: a pilot uncontrolled trial. Am J Kidney Dis. 2010 Dec. 56(6):1095-9. [Medline].

  32. Abe S. Pregnancy in IgA nephropathy. Kidney Int. 1991 Dec. 40(6):1098-102. [Medline].

  33. Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant. 2006 Nov. 6(11):2535-42. [Medline].

  34. Odum J, Peh CA, Clarkson AR, et al. Recurrent mesangial IgA nephritis following renal transplantation. Nephrol Dial Transplant. 1994. 9(3):309-12. [Medline].

  35. Ponticelli C, Traversi L, Feliciani A, Cesana BM, Banfi G, Tarantino A. Kidney transplantation in patients with IgA mesangial glomerulonephritis. Kidney Int. 2001 Nov. 60(5):1948-54. [Medline].

  36. Geddes CC, Rauta V, Gronhagen-Riska C, Bartosik LP, Jardine AG, Ibels LS. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant. 2003 Aug. 18(8):1541-8. [Medline].

  37. Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001 Apr 15. 110(6):434-7. [Medline].

  38. Wakai K, Kawamura T, Endoh M, et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant. 2006 Oct. 21(10):2800-8. [Medline].

  39. Alamartine E, Sabatier JC, Berthoux FC. Comparison of pathological lesions on repeated renal biopsies in 73 patients with primary IgA glomerulonephritis: value of quantitative scoring and approach to final prognosis. Clin Nephrol. 1990 Aug. 34(2):45-51. [Medline].

  40. Rekola S, Bergstrand A, Bucht H. Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA clearance. Kidney Int. 1991 Dec. 40(6):1050-4. [Medline].

  41. Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant. 2002 Jul. 17(7):1197-203. [Medline].

Glomerulus with mesangial hypercellularity and intact capillary loops. Trichrome Stain, original magnification 400x. Image courtesy of Patrick D Walker, MD.
Mesangial deposits of immunoglobulin A (IgA). Fluoresceinated Anti-IgA Antibody, Immunofluorescence microscopy, original magnification 400x. Image courtesy of Patrick D Walker, MD.
Electron photomicrograph showing mesangial electron dense deposits (arrow). Uranyl acetate and lead citrate stain, original magnification 12,000x. Image courtesy of Patrick D Walker, MD.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.